NCCM
MYGN icon

Nine Chapters Capital Management’s Myriad Genetics MYGN Stock Holding History

Nine Chapters Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-43,700
Closed -$839K – 130
2017
Q1 		$839K Buy
43,700
+5,400
+14% +$95.7K 1.13% 12
2016
Q4 		$638K Buy
+38,300
New +$693K 1.08% 23
2013
Q4 		– Sell
-77,900
Closed -$1.83M – 896
2013
Q3 		$1.83M Buy
77,900
+61,700
+381% +$1.75M 0.21% 138
2013
Q2 		$435K Buy
+16,200
New +$470K 0.08% 372

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Nine Chapters Capital Management's MYGN Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Myriad Genetics (MYGN) in Q2 2017, closing a stake of 43,700 shares — an estimated $839K sold.

Nine Chapters Capital Management first reported a position in MYGN in Q2 2013 and held it in 4 quarters. The position peaked at $1.83M in Q3 2013. 239 funds tracked by Wall St. Rank hold MYGN as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Myriad Genetics position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 43,700 Myriad Genetics shares in Q2 2017, an estimated $839K.
  • Nine Chapters Capital Management first reported a position in Myriad Genetics in Q2 2013 and held it in 4 quarters.
  • Nine Chapters Capital Management's Myriad Genetics position peaked at $1.83M in Q3 2013.
  • 239 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.